Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials

Overview

Journal CNS Drugs

Specialties Neurology
Pharmacology

Date 2015 Jul 19

PMID 26187557

Citations 20

Authors

Andreas Soejitno

Anastasia Tjan

Thomas Eko Purwata

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is one of the most debilitating neurodegenerative diseases and is predicted to affect 1 in 85 people by 2050. Despite much effort to discover a therapeutic strategy to prevent progression or to cure AD, to date no effective disease-modifying agent is available that can prevent, halt, or reverse the cognitive and functional decline of patients with AD. Several underlying etiologies to this failure are proposed. First, accumulating evidence from past trials suggests a preventive as opposed to therapeutic paradigm, and the precise temporal and mechanistic relationship of β-amyloid (Aβ) and tau protein should be elucidated to confirm this hypothesis. Second, we are in urgent need of revised diagnostic criteria to support future trials. Third, various technical and methodological improvements are required, based on the lessons learned from previous failed trials.

Citing Articles

Transcriptomic and glycomic analyses highlight pathway-specific glycosylation alterations unique to Alzheimer's disease.

Tang X, Tena J, Di Lucente J, Maezawa I, Harvey D, Jin L Sci Rep. 2023; 13(1):7816.

PMID: 37188790 PMC: 10185676. DOI: 10.1038/s41598-023-34787-4.

Retinal arteriolar parameters as a surrogate marker of intracranial vascular pathology.

Abdelhak A, Solomon I, Montes S, Saias A, Cordano C, Asken B Alzheimers Dement (Amst). 2022; 14(1):e12338.

PMID: 35814617 PMC: 9257197. DOI: 10.1002/dad2.12338.

Next-generation antibody-based therapies in neurology.

Ruck T, Nimmerjahn F, Wiendl H, Lunemann J Brain. 2021; 145(4):1229-1241.

PMID: 34928330 PMC: 9630709. DOI: 10.1093/brain/awab465.

MMP9 modulation improves specific neurobehavioral deficits in a mouse model of Alzheimer's disease.

Ringland C, Schweig J, Eisenbaum M, Paris D, Ait-Ghezala G, Mullan M BMC Neurosci. 2021; 22(1):39.

PMID: 34034683 PMC: 8152085. DOI: 10.1186/s12868-021-00643-2.

Integrative glycoproteomics reveals protein N-glycosylation aberrations and glycoproteomic network alterations in Alzheimer's disease.

Zhang Q, Ma C, Chin L, Li L Sci Adv. 2020; 6(40).

PMID: 33008897 PMC: 7852392. DOI: 10.1126/sciadv.abc5802.

References

Stancu I, Ris L, Vasconcelos B, Marinangeli C, Goeminne L, Laporte V . Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease. FASEB J. 2014; 28(6):2620-31. DOI: 10.1096/fj.13-246702. View

Terry R, Masliah E, Salmon D, Butters N, DeTeresa R, Hill R . Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30(4):572-80. DOI: 10.1002/ana.410300410. View

Desikan R, McEvoy L, Thompson W, Holland D, Brewer J, Aisen P . Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012; 69(6):709-13. PMC: 3423526. DOI: 10.1001/archneurol.2011.3354. View

Racke M, Boone L, Hepburn D, Parsadainian M, Bryan M, Ness D . Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005; 25(3):629-36. PMC: 6725332. DOI: 10.1523/JNEUROSCI.4337-04.2005. View

Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K . Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003; 15(3):169-76. DOI: 10.1159/000068478. View

Fagan A, Roe C, Xiong C, Mintun M, Morris J, Holtzman D . Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007; 64(3):343-9. DOI: 10.1001/archneur.64.3.noc60123. View

Watt A, Crespi G, Down R, Ascher D, Gunn A, Perez K . Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?. Acta Neuropathol. 2014; 127(6):803-10. DOI: 10.1007/s00401-014-1290-2. View

Villemagne V, Burnham S, Bourgeat P, Brown B, Ellis K, Salvado O . Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013; 12(4):357-67. DOI: 10.1016/S1474-4422(13)70044-9. View

Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson L, Nilsson L . 15-year longitudinal study of blood pressure and dementia. Lancet. 1996; 347(9009):1141-5. DOI: 10.1016/s0140-6736(96)90608-x. View

10.

Coric V, van Dyck C, Salloway S, Andreasen N, Brody M, Richter R . Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012; 69(11):1430-40. DOI: 10.1001/archneurol.2012.2194. View

11.

Patton R, Kalback W, Esh C, Kokjohn T, Van Vickle G, Luehrs D . Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006; 169(3):1048-63. PMC: 1698828. DOI: 10.2353/ajpath.2006.060269. View

12.

Krop I, Demuth T, Guthrie T, Wen P, Mason W, Chinnaiyan P . Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012; 30(19):2307-13. DOI: 10.1200/JCO.2011.39.1540. View

13.

Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello A, Antoniello K . An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci. 2012; 32(28):9677-89. PMC: 6622286. DOI: 10.1523/JNEUROSCI.4742-11.2012. View

14.

Pievani M, de Haan W, Wu T, Seeley W, Frisoni G . Functional network disruption in the degenerative dementias. Lancet Neurol. 2011; 10(9):829-43. PMC: 3219874. DOI: 10.1016/S1474-4422(11)70158-2. View

15.

Orgogozo J, Gilman S, Dartigues J, Laurent B, Puel M, Kirby L . Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003; 61(1):46-54. DOI: 10.1212/01.wnl.0000073623.84147.a8. View

16.

Lue L, Kuo Y, Roher A, Brachova L, Shen Y, Sue L . Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999; 155(3):853-62. PMC: 1866907. DOI: 10.1016/s0002-9440(10)65184-x. View

17.

Henley D, May P, Dean R, Siemers E . Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2009; 10(10):1657-64. DOI: 10.1517/14656560903044982. View

18.

Weng A, Ferrando A, Lee W, Morris 4th J, Silverman L, Sanchez-Irizarry C . Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-71. DOI: 10.1126/science.1102160. View

19.

Kuhn P, Koroniak K, Hogl S, Colombo A, Zeitschel U, Willem M . Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons. EMBO J. 2012; 31(14):3157-68. PMC: 3400020. DOI: 10.1038/emboj.2012.173. View

20.

Karran E, Mercken M, De Strooper B . The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011; 10(9):698-712. DOI: 10.1038/nrd3505. View